Llwytho...
非小细胞肺癌中microRNAs与EGFR-TKIs继发性耐药机制的研究进展
In recent years, in non-small cell lung cancer (NSCLC) targeted therapy, especially in patients with epidermal growth factor receptor (EGFR) mutations, EGFR-tyrosine kinase inhibitors (TKI) more and more come into the clinical treatment, but EGFR-TKI resistance not only influence the drug sensitivit...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Zhongguo Fei Ai Za Zhi |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
中国肺癌杂志编辑部
2014
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6000411/ https://ncbi.nlm.nih.gov/pubmed/25539612 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2014.12.07 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|